Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 25Carcinoma, Intraductal, Noninfiltrating 3Ovarian Neoplasms 2Endometrial Neoplasms 2Breast Neoplasms, Male 2Breast Diseases 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Low Grade Serous Ovarian Cancer 1Locoregional Recurrence 1Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1HR Positive HER2 Negative Advanced Breast Cancer 1HER2 Negative Breast Cancer 1Fallopian Tube Neoplasms 1Endometrial Stromal Tumors 1ER+ Breast Cancer 1Anatomic Stage III Breast Cancer AJCC v8 1Anatomic Stage II Breast Cancer AJCC v8 1Advanced Breast Cancer 1

Interventions

Specimen Handling 2ribociclib 1pembrolizumab 1exemestane 1durvalumab 1Watchful Waiting 1Taxes 1Paclitaxel 1Observation 1Magnetic Resonance Spectroscopy 1Letrozole 1Immunoglobulin G 1High-Energy Shock Waves 1Genetic Testing 1Drug Therapy 1Doxorubicin 1Disulfides 1Cyclophosphamide 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Anatomic Stage II Breast Cancer AJCC v8 × Anastrozole × Clear all
NCT07391774 2026-06-05

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

National Cancer Institute (NCI)

Phase 3 Recruiting
1,978 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡